Risk of scar in the comparison of age-related macular degeneration treatments trials

To describe risk factors for scar in eyes treated with ranibizumab or bevacizumab for neovascular age-related macular degeneration (AMD). Prospective cohort study within a randomized clinical trial. Patients with no scar on color fundus photography (CFP) or fluorescein angiography (FA) at enrollment...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Ophthalmology (Rochester, Minn.) Ročník 121; číslo 3; s. 656
Hlavní autori:	Daniel, Ebenezer, Toth, Cynthia A, Grunwald, Juan E, Jaffe, Glenn J, Martin, Daniel F, Fine, Stuart L, Huang, Jiayan, Ying, Gui-shuang, Hagstrom, Stephanie A, Winter, Katrina, Maguire, Maureen G
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.03.2014
Predmet:	Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Bevacizumab Cicatrix - diagnosis Cicatrix - etiology Cohort Studies Female Fibrosis Fluorescein Angiography Genotype Humans Incidence Intravitreal Injections Male Middle Aged Postoperative Complications Prospective Studies Ranibizumab Retina - pathology Risk Factors Tomography, Optical Coherence Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - genetics
ISSN:	1549-4713, 1549-4713
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!